AEterna
Zentaris, Inc. could be a late-stage drug development company, that makes a specialty
of medical specialty and endocrine medical care. The corporate investigates
treatments for varied cancers which incorporates body part, myeloma, mucous
membrane, ovarian, bladder cancer and prostate. Its pipeline encompasses
compounds in the least stages of development from drug discovery through marketing
product. The corporate focus on the event of perifosine, AEZS-108 and AEZS-130.
AEterna Zentaris was supported on Sep twelve, 1990 and is located in Quebec,
Canada.
AEterna
Zentaris (NASDAQ:AEZS) reported EPS of
-1.169. For this year, the corporation is predicted to report EPS of -0.90. For
consequent Quarter and Next Season, the business is expected to review EPS of
-0.32 and -1.11 severally. At Current value, AEZS is in the distance of +13.58%
from its 50-day Moving Average value of $2.1747 and -9.72% from its 200-day
Moving Average value of $2.7358.
Aeterna
Zentaris (NASDAQ:AEZS) has reached AN agreement with the FDA on a Special
Protocol Assessment for a future part three registration trial in carcinoma
with its antibiotic amide conjugate, AEZS-108. The accord states that the
planned trial protocol style, clinical endpoints and planned analyses are all
acceptable to the authority in support of a restrictive submission. AEZS-108
represents a replacement targeting conception in medical specialty employing a
hybrid molecule composed of an artificial amide carrier and a widely known therapeutic
agent, antibiotic. AEZS-108 is that the 1st Endovenous drug in advanced
clinical development that directs the therapeutic agent specifically to
interstitial cell-stimulating hormone cathartic endocrine (LHRH)-receptor
expressing tumors, leading to a lot of targeted treatment with less harm to
healthy tissue. The merchandise has with success completed part a pair of
studies for the treatment of female internal reproductive organ and carcinoma
and also the Company are presently designing a part three trial in carcinoma
below a Special Protocol Assessment.
